Last reviewed · How we verify

telbivudine (ROADMAP) — Competitive Intelligence Brief

telbivudine (ROADMAP) (telbivudine (ROADMAP)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI). Area: Virology / Hepatology.

marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase Virology / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

telbivudine (ROADMAP) (telbivudine (ROADMAP)) — Nanfang Hospital, Southern Medical University. Telbivudine is a nucleoside reverse transcriptase inhibitor that blocks viral reverse transcriptase to inhibit hepatitis B virus replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
telbivudine (ROADMAP) TARGET telbivudine (ROADMAP) Nanfang Hospital, Southern Medical University marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase
entecavir (BARACLUDE®) entecavir (BARACLUDE®) National Taiwan University Hospital marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase / HBV polymerase
blank Baraclude tablets blank Baraclude tablets Chia Tai Tianqing Pharmaceutical Group Co., Ltd. marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase / HBV polymerase
Adefovir dipivoxil (adefovir) Adefovir dipivoxil (adefovir) Merck Sharp & Dohme LLC marketed Nucleotide reverse transcriptase inhibitor Hepatitis B virus reverse transcriptase / DNA polymerase
Tacrolimus &entecavir Tacrolimus &entecavir Guangdong Provincial People's Hospital marketed Combination immunosuppressant and antiviral Calcineurin (tacrolimus); Hepatitis B virus reverse transcriptase (entecavir)
Hepsera and lamivudine Hepsera and lamivudine University of Washington marketed Nucleoside/nucleotide reverse transcriptase inhibitor Hepatitis B virus reverse transcriptase
Baraclude tablets Baraclude tablets Chia Tai Tianqing Pharmaceutical Group Co., Ltd. marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase / HBV polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) class)

  1. French National Agency for Research on AIDS and Viral Hepatitis · 3 drugs in this class
  2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  3. ViiV Healthcare · 2 drugs in this class
  4. Nanfang Hospital, Southern Medical University · 2 drugs in this class
  5. Asan Medical Center · 1 drug in this class
  6. Dong-A ST Co., Ltd. · 1 drug in this class
  7. Bristol-Myers Squibb · 1 drug in this class
  8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  9. Fu-Sheng Wang · 1 drug in this class
  10. Avexa · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). telbivudine (ROADMAP) — Competitive Intelligence Brief. https://druglandscape.com/ci/telbivudine-roadmap. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: